Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Apr;87(4):1462-6.
doi: 10.1172/JCI115153.

CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual

Affiliations

CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual

C E Mackewicz et al. J Clin Invest. 1991 Apr.

Abstract

The extent of antiviral activity exhibited in vitro by CD8+lymphocytes from individuals infected by HIV-1 correlates significantly with their clinical status. CD8+ lymphocytes from asymptomatic subjects were found to inhibit HIV-1 replication by 90% or greater at effector/target (E/T) ratios ranging from as low as 0.05 to 0.25. CD8+ cells from 17 of 19 (89%) of these subjects suppressed replication at an E/T ratio of 0.10 or less. CD8+ lymphocytes from symptomatic patients (non-AIDS) inhibited HIV-1 replication at E/T ratios ranging from 0.05 to 1.0, and CD8+ cells from 8 of 13 (62%) required ratios greater than 0.10. As a group, patients with AIDS exhibited the lowest degree of anti-HIV activity with their CD8+ lymphocytes. The effective range of E/T ratios from AIDS patients was 0.10-2.0, and 9 of 10 (90%) required E/T ratios greater than 0.25. This anti-HIV activity exhibited by CD8+ cells also correlated significantly with the subject's peripheral blood CD4+ cell count. The relative extent of CD8+ cell anti-HIV-1 activity was not found dependent on variations in the CD4+ target cells and viruses used. These findings suggest that the decreased CD8+ cell antiviral activity is related to progression to disease in HIV-infected individuals.

PubMed Disclaimer

References

    1. J Infect Dis. 1988 Jun;157(6):1260-4 - PubMed
    1. Nature. 1978 May 18;273(5659):238-9 - PubMed
    1. J Immunol. 1987 Oct 1;139(7):2458-63 - PubMed
    1. J Immunol. 1988 Apr 1;140(7):2237-42 - PubMed
    1. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5535-9 - PubMed

Publication types

MeSH terms